Sodium–Glucose Cotransporter-2 Inhibitors After Acute Myocardial Infarction
Sodium–glucose cotransporter-2 inhibitors (SGLT2i) are a specific class of drugs originally developed for treating type 2 diabetes mellitus. Subsequently, studies demonstrated that their action was not limited to glycemic control but could also have positive effects on other specific outcomes, parti...
Saved in:
| Main Authors: | Nicia I. Profili, Roberto Castelli, Roberto Manetti, Marta C. Sircana, Michela Pagni, Gemma Lisa Sechi, Antonio Gidaro, Costantino Cossu, Francesco Bella, Alessandro P. Delitala |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-03-01
|
| Series: | Biomedicines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2227-9059/13/3/720 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Sodium-Glucose Cotransporter-2 Inhibitors in Diabetic Patients with Heart Failure: An Update
by: Nicia I. Profili, et al.
Published: (2024-10-01) -
Sodium glucose cotransporter 2 inhibitors are associated with renal stabilization in heart transplantation
by: Lisa M. Raven, MBBS, FRACP, et al.
Published: (2025-05-01) -
Sodium–glucose cotransporter-2 inhibitors improve cardiovascular outcomes post-acute coronary syndrome complicated by acute heart failure
by: Alaa Rahhal, et al.
Published: (2024-05-01) -
Corrigendum: Sodium–glucose cotransporter-2 inhibitors improve cardiovascular outcomes post-acute coronary syndrome complicated by acute heart failure
by: Alaa Rahhal, et al.
Published: (2025-03-01) -
Sodium-glucose cotransporter 2 inhibitor for the treatment of diabetic nephropathy
by: Kong Ling-li, et al.
Published: (2021-01-01)